- Home
- IMVT vs SRRK Comparison
IMVT vs SRRK Comparison
Compare IMVT & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- SRRK
- Stock Information
- Founded
- IMVT 2018
- SRRK 2012
- Country
- IMVT United States
- SRRK United States
- Employees
- IMVT N/A
- SRRK N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMVT Health Care
- SRRK Health Care
- Exchange
- IMVT Nasdaq
- SRRK Nasdaq
- Market Cap
- IMVT 2.8B
- SRRK 3.2B
- IPO Year
- IMVT N/A
- SRRK 2018
- Fundamental
- Price
- IMVT $16.95
- SRRK $35.54
- Analyst Decision
- IMVT Buy
- SRRK Strong Buy
- Analyst Count
- IMVT 10
- SRRK 6
- Target Price
- IMVT $40.14
- SRRK $42.17
- AVG Volume (30 Days)
- IMVT 1.4M
- SRRK 1.5M
- Earning Date
- IMVT 08-05-2025
- SRRK 08-07-2025
- Dividend Yield
- IMVT N/A
- SRRK N/A
- EPS Growth
- IMVT N/A
- SRRK N/A
- EPS
- IMVT N/A
- SRRK N/A
- Revenue
- IMVT N/A
- SRRK N/A
- Revenue This Year
- IMVT N/A
- SRRK N/A
- Revenue Next Year
- IMVT N/A
- SRRK $502.60
- P/E Ratio
- IMVT N/A
- SRRK N/A
- Revenue Growth
- IMVT N/A
- SRRK N/A
- 52 Week Low
- IMVT $12.72
- SRRK $6.76
- 52 Week High
- IMVT $34.47
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- IMVT 60.86
- SRRK 58.40
- Support Level
- IMVT $15.80
- SRRK $33.50
- Resistance Level
- IMVT $17.06
- SRRK $36.93
- Average True Range (ATR)
- IMVT 0.68
- SRRK 2.05
- MACD
- IMVT 0.07
- SRRK 0.12
- Stochastic Oscillator
- IMVT 86.70
- SRRK 83.26
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.